Beyoglu Eye Research and Education Hospital, Istanbul, Turkey.
Am J Ophthalmol. 2011 Dec;152(6):976-981.e2. doi: 10.1016/j.ajo.2011.05.027. Epub 2011 Sep 8.
To evaluate the prophylactic efficacy of selective laser trabeculoplasty for preventing an increase in intraocular pressure (IOP) after intravitreal triamcinolone acetonide injection.
Prospective, comparative, interventional case series.
We studied 31 eyes with a baseline IOP of 21 mm Hg or more of 31 patients for which intravitreal triamcinolone acetonide injection was planned for diabetic macular edema. The patients were divided into 2 groups, a study group and control group. The study group comprised 15 eyes of 15 patients that underwent selective laser trabeculoplasty a mean of 8.3 ± 4.1 days before intravitreal triamcinolone acetonide injection. The control group comprised 16 eyes of 16 patients who underwent only intravitreal triamcinolone acetonide injection. Main outcomes measures were mean IOP and number of patients requiring antiglaucomatous therapy.
Mean baseline IOP was 21.6 ± 0.9 mm Hg in the study group and 21.5 ± 0.8 mm Hg in the control group (P = .98). Mean IOP at 1 day after injection was 17.0 ± 2.0 mm Hg in the study group and 19.5 ± 4.3 mm Hg in the control group (P = .23). Mean IOP at 1 week after injection was 16.9 ± 1.7 mm Hg and 18.4 ± 4.0 mm Hg, respectively (P = .49); mean IOP at 1 month after injection was 16.4 ± 1.5 mm Hg and 20.8 ± 5.6 mm Hg, respectively (P = .003); mean IOP at 3 months after injection was 15.8 ± 2.5 mm Hg and 18.3 ± 5.5 mm Hg, respectively (P = .01); and mean IOP at 6 months after injection was 15.7 ± 1.4 mm Hg and 17.1 ± 1.5 mm Hg, respectively (P = .03). The number of patients requiring antiglaucomatous therapy during follow-up was 0 of 15 eyes in the study group and 8 of 16 eyes in the control group (P = .001).
The IOP elevation after intravitreal triamcinolone acetonide injection may be prevented by performing selective laser trabeculoplasty before intravitreal triamcinolone acetonide injection, especially in cases with a baseline IOP of 21 mm Hg or more.
评估选择性激光小梁成形术预防曲安奈德玻璃体注药后眼压升高的效果。
前瞻性、对照、干预性病例系列研究。
我们研究了 31 名患者的 31 只眼,这些患者的基线眼压为 21mmHg 或更高,他们计划接受曲安奈德玻璃体注药治疗糖尿病性黄斑水肿。将患者分为研究组和对照组。研究组包括 15 只眼,其中 15 名患者在玻璃体注药前平均 8.3±4.1 天接受选择性激光小梁成形术。对照组包括 16 只眼,其中 16 名患者仅接受玻璃体注药。主要观察指标为平均眼压和需要抗青光眼治疗的患者人数。
研究组的基线眼压为 21.6±0.9mmHg,对照组为 21.5±0.8mmHg(P=0.98)。注药后 1 天的平均眼压为研究组 17.0±2.0mmHg,对照组 19.5±4.3mmHg(P=0.23)。注药后 1 周的平均眼压分别为 16.9±1.7mmHg 和 18.4±4.0mmHg(P=0.49);注药后 1 个月的平均眼压分别为 16.4±1.5mmHg 和 20.8±5.6mmHg(P=0.003);注药后 3 个月的平均眼压分别为 15.8±2.5mmHg 和 18.3±5.5mmHg(P=0.01);注药后 6 个月的平均眼压分别为 15.7±1.4mmHg 和 17.1±1.5mmHg(P=0.03)。在研究组的 15 只眼中,有 0 只眼在随访期间需要抗青光眼治疗,而对照组的 16 只眼中有 8 只眼需要治疗(P=0.001)。
在玻璃体注药前进行选择性激光小梁成形术,特别是在基线眼压为 21mmHg 或更高的情况下,可能预防曲安奈德玻璃体注药后眼压升高。